These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 901587)

  • 1. On the interaction of drugs with the cholinergic nervous system--IV. Tolerance to oxotremorine in mice: in vivo and in vitro studies.
    Maayani S; Egozi Y; Pinchasi I; Sokolovsky M
    Biochem Pharmacol; 1977 Sep; 26(18):1681-7. PubMed ID: 901587
    [No Abstract]   [Full Text] [Related]  

  • 2. On the interaction of drugs with the cholinergic nervous system--V. Characterization of some effects induced by physostigmine in mice: in vivo and in vitro studies.
    Maayani S; Egozi Y; Pinchasi I; Sokolovsky M
    Biochem Pharmacol; 1978 Jan; 27(2):203-11. PubMed ID: 623676
    [No Abstract]   [Full Text] [Related]  

  • 3. On the interaction of drugs with the cholinergic nervous system--III. Tolerance to phencyclidine derivatives: in vivo and in vitro studies.
    Pinchasi I; Maayani S; Sokolovsky M
    Biochem Pharmacol; 1977 Sep; 26(18):1671-9. PubMed ID: 901586
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological study of oral CDP-choline. Interaction with oxotremorine on the parasympathetic system.
    Tornos ME; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1983; 33(7A):1026-9. PubMed ID: 6684457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response to cholinergic stimulation in psychogenitically selected rat lines.
    Martin JR; Driscoll P; Gentsch C
    Psychopharmacology (Berl); 1984; 83(3):262-7. PubMed ID: 6433388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic scopolamine treatment and brain cholinergic function.
    Marks MJ; O'Connor MF; Artman LD; Burch JB; Collins AC
    Pharmacol Biochem Behav; 1984 May; 20(5):771-7. PubMed ID: 6739517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings: On the action of oxotremorine on the cholinergic system of rat brain.
    Pleul O
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R75. PubMed ID: 4276628
    [No Abstract]   [Full Text] [Related]  

  • 8. Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice.
    Sánchez C; Meier E
    Pharmacol Toxicol; 1993; 72(4-5):262-7. PubMed ID: 8372044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.
    Ringdahl B; Roch M; Jenden DJ
    J Pharmacol Exp Ther; 1987 Aug; 242(2):464-71. PubMed ID: 3612545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic adaptations to chronic oxotremorine infusion.
    Marks MJ; Artman LD; Patinkin DM; Collins AC
    J Pharmacol Exp Ther; 1981 Aug; 218(2):337-43. PubMed ID: 7252834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.
    Howell G; West L; Jenkins C; Lineberry B; Yokum D; Rockhold R
    BMC Pharmacol; 2005 Aug; 5():13. PubMed ID: 16109168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A; Ogren SO
    J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central cholinergic mechanisms in electrical self-stimulation and in drug-induced tremor in rats.
    Wishart TB; Herberg LJ
    Pharmacol Biochem Behav; 1979 Dec; 11(6):625-9. PubMed ID: 538051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding.
    Freedman SB; Harley EA; Patel S
    Eur J Pharmacol; 1989 Dec; 174(2-3):253-60. PubMed ID: 2630302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine.
    Marks MJ; Collins AC
    Pharmacol Biochem Behav; 1985 Feb; 22(2):283-91. PubMed ID: 3983219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro studies on the antimuscarinic activity of some amino esters of benzilic acid.
    Rehavi M; Yaavetz B; Kloog Y; Maayani S; Sokolovsky M
    Biochem Pharmacol; 1978; 27(8):1117-24. PubMed ID: 697913
    [No Abstract]   [Full Text] [Related]  

  • 17. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels.
    Laplante F; Nakagawasai O; Srivastava LK; Quirion R
    Neuropsychopharmacology; 2005 Jun; 30(6):1076-87. PubMed ID: 15637638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic antidepressants as antimuscarinic drugs: in vivo and in vitro studies.
    Rehavi M; Maayani S; Sokolovsky M
    Biochem Pharmacol; 1977 Sep; 26(17):1559-67. PubMed ID: 901576
    [No Abstract]   [Full Text] [Related]  

  • 19. Muscarinic actions and receptor binding of the enantiomers of BM 130, an alkylating analog of oxotremorine.
    Ringdahl B; Katz ED; Roch M; Jenden DJ
    J Pharmacol Exp Ther; 1989 Apr; 249(1):210-5. PubMed ID: 2709331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BM-5, a centrally active partial muscarinic agonist with low tremorogenic activity. In vivo and in vitro studies.
    Engström C; Undén A; Ladinsky H; Consolo S; Bartfai T
    Psychopharmacology (Berl); 1987; 91(2):161-7. PubMed ID: 3107028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.